Skip to main content
. 2022 Feb 26;39(4):987–993. doi: 10.1007/s10815-022-02440-0

Table 2.

Pregnancy, live birth and miscarriage rate among the 3 groups

Group 1
Biopsied Day-5—Vitrified
Group 2
Vitrified day 5-Biopsied-
Re-Vitrified
Group 3
Vitrified Day 3- Biopsied day 5- Re-Vitrified
(GEE) p,
OR, CI 95%
Pregnancy rate 65.2% (294/451) * 67.8% (99/146) 66.0% (64/97)
Ref. group 1.09 (0.62–1.91), p = 0.77 0.97 (0.61–1.53), p = 0.88 Unadjusted
1.07 (0.68–1.64), p = 0.78 1.22 (0.74–1.99), p = 0.44 Adjusted
Clinical pregnancy rate 62.3% (281/451) 62.3% (91/146) 62.9% (61/97)
Ref. Group 1.00, (0.66–1.50), p = 0.99 1.02, (0.65–1.61), p = 0.91 Unadjusted
0.89, (0.58–1.37), p = 0.60 1.21, (0.75–1.96), p = 0.44 Adjusted
Live birth rate 56.8% (256/451) 54.8% (80/146) 56.7% (55/97)
Ref. Group 0.93 (0.55–1.56), p = 0.77 1.00 (0.65–1.55), p = 0.99 Unadjusted
0.85 (0.56–1.28), p = 0.43 1.15 (0.73–1.80), p = 0.54 Adjusted
Clinical miscarriage 7.8% (22/281) 11.0% (10/91) 9.8% (6/61)
Ref. Group 1.45, (0.67–3.17), p = 0.35 1.28, (0.50–3.30), p = 0.60 Unadjusted
1.35, (0.59–3.06), p = 0.47 1.24, (0.50–3.10), p = 0.64 Adjusted

The outcomes are presented as unadjusted and adjusted values for age at the oocyte collection, BMI, endometrial thickness, semen source, endometrial preparation method, biopsy day, embryo quality category and any of their 2-way interactions that were statistically significant.

*The percentages for reproductive outcomes are used to demonstrate the magnitude of the outcomes and are not directly comparable. Since patients had more than one treatment cycle included in the study and as the treatment cycles of the same patient are not independent of each other, the outcomes can be compared with the Odd Ratios from GEE.